Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.
InflaRx N.V. (Nasdaq: IFRX) is a biopharmaceutical company that regularly issues news on its clinical programs targeting the complement system, particularly the C5a/C5aR axis. Company updates highlight progress with its oral C5a receptor inhibitor izicopan (also referenced as INF904) and its intravenously delivered anti-C5a monoclonal antibody vilobelimab, including GOHIBIC (vilobelimab) for SARS-CoV-2-induced acute respiratory distress syndrome in the European Union.
News about InflaRx often covers clinical trial milestones, such as Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria for izicopan, as well as analyses of Phase 3 data for vilobelimab in pyoderma gangrenosum. Releases also describe regulatory interactions, including anticipated discussions with the U.S. Food and Drug Administration, and strategic decisions about prioritizing resources toward izicopan and adjusting spending on GOHIBIC (vilobelimab).
Investors following IFRX news can expect announcements on clinical data readouts, participation in healthcare and investor conferences, and business updates related to funding, cash runway and partnering activities. InflaRx’s communications have included information on BARDA-supported studies in acute respiratory distress syndrome, co-development activities for an anti-C5a antibody in China, and notices regarding Nasdaq listing requirements.
This news feed aggregates InflaRx’s press releases and related coverage so readers can review clinical developments, regulatory updates and corporate actions in one place. For those tracking complement-targeted therapeutics, IFRX news provides insight into how the company is advancing its C5a and C5aR inhibitor programs across dermatologic and respiratory indications and how it is aligning its strategy and capital allocation with these priorities.
InflaRx (Nasdaq: IFRX) will participate in the Leerink Partners Global Healthcare Conference in Miami, March 8-11, 2026, with a fireside chat on March 9 at 9:20 AM ET and one-on-one investor meetings the same day.
Live streaming and replay of the fireside chat will be available via a company link; investor relations contacts are provided for meeting requests.
InflaRx (Nasdaq: IFRX) will participate in investor conferences in February 2026, offering live presentations and one-on-one meetings. Key appearances include a fireside chat at the Guggenheim Biotech Summit on Feb 11, 2026 at 11:30 AM ET and a virtual presentation at Oppenheimer on Feb 25, 2026 at 8:40 AM ET. Replay links and details for one-on-one meetings are available from the company. The release also summarizes InflaRx's lead programs, izicopan and vilobelimab, and corporate locations in Germany and the U.S.
InflaRx (Nasdaq: IFRX) is refocusing resources on its oral C5aR inhibitor izicopan, aiming for Phase 2b readiness in hidradenitis suppurativa (HS) and broader inflammation & immunology (I&I) indications. The company is initiating a PK bridging study in China in 2026 to enable expedited PoC studies and is pursuing partner discussions to accelerate development. InflaRx is executing an ~30% workforce reduction, expects a one-time charge of ~$7 million, and says the actions extend its cash runway to mid-2027. A virtual Capital Markets Day is planned for spring 2026.
InflaRx (Nasdaq: IFRX) provided updated analyses from its terminated Phase 3 study of vilobelimab in ulcerative pyoderma gangrenosum (PG). The trial was stopped early for futility after enrolling 54 patients (30 completed 6 months). The prespecified primary endpoint (complete target ulcer closure on two consecutive visits) favored vilobelimab 20.8% vs placebo 16.7% (p=NS). Post-hoc analyses showed statistically significant reductions in target ulcer volume: MMRM percent change overall -45.4% (p=0.0428) and weekly differences from Week 14 to 26 (e.g., Week 26 -63.2%, p=0.0122); ANCOVAs for volume and area were p=0.0111 and p=0.0072. Safety was generally well tolerated with similar serious related TEAEs (6.3% vs 4.5%). InflaRx plans FDA discussions and expects future PG work would require a partner.
InflaRx (Nasdaq: IFRX) announced the World Health Organization has granted the international nonproprietary name izicopan for its oral C5aR inhibitor formerly known as INF904; the name will be published in the WHO recommended INN list.
Izicopan has shown tolerability in first‑in‑human single doses (3–240 mg) and multiple doses (30 mg once daily to 90 mg twice daily), pharmacokinetic/pharmacodynamic support with a ≥90% blockade of C5a‑induced neutrophil activation over 14 days, and topline Phase 2a signals of clinical activity in hidradenitis suppurativa and chronic spontaneous urticaria.
InflaRx (Nasdaq: IFRX) reported positive topline Phase 2a results for oral C5aR inhibitor INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) on Nov 10, 2025. Data from 29 HS and 30 CSU patients showed rapid reductions in lesion counts and symptoms over 4 weeks with durable effects at Week 8.
Key 4-week signals: HiSCR50 28% (all doses), HiSCR50 Week 8 44% (n=25); AN change −5.1 (all doses); dT100 29%; NRS30 pain response 66%; CSU UAS7 change −10.4 (all doses) and −15.4 in severe CSU (60 mg). No serious adverse events reported. Company targets Phase 2b initiation in HS in 2026 and continues partner discussions.
InflaRx (Nasdaq: IFRX) expects to report topline Phase 2a clinical data for oral C5aR inhibitor INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) in a pre-market press release on November 10, 2025.
The company will host a webcast and slide presentation on November 10, 2025 at 8:00 AM EST / 2:00 PM CET and also expects to publish third quarter 2025 financial results via Form 6-K the same day pre-market.
InflaRx (Nasdaq: IFRX) will participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MA from November 10–12, 2025. The company will appear in a fireside chat on November 11 at 2:30 PM ET and will hold one-on-one investor meetings the same day. A live stream and replay link for the fireside chat will be provided.
InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics that target the complement system, developing vilobelimab (intravenous anti-C5a antibody) and INF904 (oral C5a receptor inhibitor). The company has offices in Jena and Munich, Germany, and Ann Arbor, MI.
InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company maintained a closing bid price of $1.00 or higher for 10 consecutive business days from August 27 to September 10, 2025.
InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor. Their key product is vilobelimab, an intravenous first-in-class anti-C5a monoclonal antibody, alongside INF904, an oral small molecule inhibitor. The company, founded in 2007, operates from offices in Jena and Munich, Germany, and Ann Arbor, Michigan.
InflaRx (NASDAQ:IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has announced its participation in two major investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference (September 3-5) with a fireside chat on September 4th at 9:10 AM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference (September 8-10) with a presentation on September 9th at 3:30 PM ET.
InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor. Their lead product, vilobelimab, is an intravenous anti-C5a monoclonal antibody, and they are also developing INF904, an oral small molecule C5a receptor inhibitor.